NO20074474L - Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav - Google Patents

Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav

Info

Publication number
NO20074474L
NO20074474L NO20074474A NO20074474A NO20074474L NO 20074474 L NO20074474 L NO 20074474L NO 20074474 A NO20074474 A NO 20074474A NO 20074474 A NO20074474 A NO 20074474A NO 20074474 L NO20074474 L NO 20074474L
Authority
NO
Norway
Prior art keywords
epha2
antibodies
bind
antigen
colons
Prior art date
Application number
NO20074474A
Other languages
English (en)
Norwegian (no)
Inventor
Jennie P Mather
Penelope E Roberts
Original Assignee
Raven Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raven Biotechnologies Inc filed Critical Raven Biotechnologies Inc
Publication of NO20074474L publication Critical patent/NO20074474L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20074474A 2005-02-04 2007-09-03 Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav NO20074474L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65004705P 2005-02-04 2005-02-04
PCT/US2006/004057 WO2006084226A2 (fr) 2005-02-04 2006-02-06 Anticorps se liant a epha2 et procedes d'utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
NO20074474L true NO20074474L (no) 2007-11-05

Family

ID=36778009

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074474A NO20074474L (no) 2005-02-04 2007-09-03 Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav

Country Status (17)

Country Link
US (3) US7569672B2 (fr)
EP (1) EP1846450B1 (fr)
JP (1) JP5342145B2 (fr)
KR (1) KR101363252B1 (fr)
CN (2) CN101155830B (fr)
AT (1) ATE551367T1 (fr)
AU (1) AU2006210460B2 (fr)
BR (1) BRPI0607450A2 (fr)
CA (1) CA2597198C (fr)
CR (1) CR9332A (fr)
HK (1) HK1108163A1 (fr)
IL (1) IL184803A (fr)
MX (1) MX2007009403A (fr)
NO (1) NO20074474L (fr)
RU (1) RU2007133108A (fr)
WO (1) WO2006084226A2 (fr)
ZA (1) ZA200707275B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
EP1928912A4 (fr) * 2005-09-07 2010-02-24 Medimmune Inc Anticorps anti-recepteur eph conjugues a des toxines
ES2673822T3 (es) * 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
AU2008207945A1 (en) 2007-01-22 2008-07-31 Macrogenics West, Inc. Human cancer stem cells
WO2008157490A1 (fr) * 2007-06-18 2008-12-24 Medimmune, Llc Traitement synergique de cellules qui expriment epha2 et erbb2
WO2009151717A2 (fr) 2008-04-02 2009-12-17 Macrogenics, Inc. Anticorps spécifiques du complexe bcr et procédés pour les utiliser
RU2525133C2 (ru) 2007-08-30 2014-08-10 Дайити Санкио Компани, Лимитед Антитело к epha2
US20110281279A1 (en) * 2007-12-21 2011-11-17 Siemens Healthcare Diagnostics Inc. CIRCULATING Epha2 RECEPTOR
JP5117917B2 (ja) 2008-04-21 2013-01-16 デクセリアルズ株式会社 保護素子及びその製造方法
JP2012504650A (ja) * 2008-10-02 2012-02-23 セルタクシス，インコーポレイテッド 免疫細胞の負の走化性の調節方法
RU2744176C2 (ru) 2008-12-19 2021-03-03 Макродженикс, Инк. Ковалентные диантитела и их применение
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
EP2498796B1 (fr) 2009-11-09 2017-12-27 AAL Scientifics, Inc. Traitement d'une cardiopathie
US20120288481A1 (en) * 2009-11-09 2012-11-15 The Brigham And Women's Hospital, Inc. Treatment of heart disease
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
CN106279416B (zh) 2010-03-04 2019-08-30 宏观基因有限公司 与b7-h3反应性的抗体、其免疫学活性片段及其用途
MX349662B (es) 2010-07-22 2017-08-08 Univ California Anticuerpos de antigenos antitumorales y metodos de uso.
CN103154025B (zh) 2010-08-02 2015-07-01 宏观基因有限公司 共价双抗体及其用途
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
AU2012300279A1 (en) 2011-08-26 2014-04-03 Merrimack Pharmaceuticals, Inc. Tandem Fc bispecific antibodies
AU2012318590B2 (en) * 2011-10-04 2017-05-18 Expression Pathology, Inc. SRM/MRM assay for the ephrin type-A receptor 2 protein
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP2016510755A (ja) 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
RU2718692C2 (ru) * 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
KR101636882B1 (ko) * 2015-06-25 2016-07-06 전남대학교 산학협력단 인간 피브로넥틴 도메인 Ⅲ 기본 골격의 신규 인간 ＥｐｈＡ2 특이적 결합 단백질 및 그의 용도
MX2018001227A (es) 2015-07-30 2018-03-26 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas.
UA125611C2 (uk) 2015-12-14 2022-05-04 Макродженікс, Інк. Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
EP3442574A4 (fr) 2016-04-15 2019-12-11 MacroGenics, Inc. Nouvelles molécules de liaison à b7-h3, leurs conjugués anticorps-médicaments et leurs procédés d'utilisation
CN110198956A (zh) * 2017-01-23 2019-09-03 学校法人东洋大学 抗epha2抗体和使用该抗epha2抗体的epha2免疫检测
EP3585431A4 (fr) 2017-02-24 2020-12-16 MacroGenics, Inc. Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations
AU2018385409A1 (en) 2017-12-12 2020-07-02 Macrogenics Inc. Bispecific CD 16-binding molecules and their use in the treatment of disease
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
JP7326764B2 (ja) * 2018-03-09 2023-08-16 東ソー株式会社 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法
US20240245722A1 (en) 2021-05-25 2024-07-25 Vaxcell-Bio Monobody-based chimeric antigen receptor and immune cell including same
KR20230140746A (ko) * 2022-03-30 2023-10-10 연세대학교 산학협력단 암전이의 검출용 신규 바이오마커

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (fr) * 1991-09-18 2005-08-02 Kenya Shitara Procede de fabrication de chimere d'anticorps humain
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE69934250T2 (de) 1998-12-22 2007-05-24 Raven Biotechnologies, Inc., South San Francisco Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
JP2003516930A (ja) 1999-08-17 2003-05-20 パーデュー・リサーチ・ファウンデーション 転移性疾患の治療
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
ES2357296T3 (es) * 1999-08-17 2011-04-25 Purdue Research Foundation Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer.
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
FR2838742B1 (fr) * 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
CA2485548A1 (fr) 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법

Also Published As

Publication number Publication date
CR9332A (es) 2008-03-18
BRPI0607450A2 (pt) 2009-09-01
JP2008529497A (ja) 2008-08-07
IL184803A (en) 2011-04-28
AU2006210460A1 (en) 2006-08-10
CA2597198A1 (fr) 2006-08-10
WO2006084226A3 (fr) 2006-11-30
MX2007009403A (es) 2007-10-02
CN101155830A (zh) 2008-04-02
KR101363252B1 (ko) 2014-02-13
ZA200707275B (en) 2009-01-28
US20100086969A1 (en) 2010-04-08
AU2006210460B2 (en) 2012-04-05
CN101155830B (zh) 2014-06-18
KR20070107721A (ko) 2007-11-07
WO2006084226A2 (fr) 2006-08-10
US8183357B2 (en) 2012-05-22
EP1846450A2 (fr) 2007-10-24
AU2006210460A2 (en) 2006-08-10
EP1846450A4 (fr) 2008-05-28
US7569672B2 (en) 2009-08-04
IL184803A0 (en) 2007-12-03
US20060177453A1 (en) 2006-08-10
EP1846450B1 (fr) 2012-03-28
CN104059150B (zh) 2018-10-02
CA2597198C (fr) 2016-06-21
US20090263391A1 (en) 2009-10-22
ATE551367T1 (de) 2012-04-15
HK1108163A1 (en) 2008-05-02
CN104059150A (zh) 2014-09-24
JP5342145B2 (ja) 2013-11-13
RU2007133108A (ru) 2009-03-10
US7776328B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
WO2017004026A8 (fr) Anticorps anti-cd 123 et conjugués et dérivés correspondants
ATE509033T1 (de) Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
UA94576C2 (ru) Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
SG170793A1 (en) Anti-mn antibodies and methods of using same
ATE461220T1 (de) Anti-egfr-antikörper
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2006084092A3 (fr) Anticorps de recepteur de l'oncostatine m
WO2006084078A3 (fr) Antigene jam-3 et anticorps se liant a celui-ci
WO2006076584A3 (fr) Antigène kid31 (carboxypeptidase m) et anticorps de liaison à celui-ci
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
WO2006110745A3 (fr) Anticorps anti-psma conjugues
WO2003024191A3 (fr) Anticorps se fixant a l'antigene cytokeratine 8 associe au cancer et procedes d'utilisation correspondants
MX2010001237A (es) Nuevos anticuerpos.
MX2021000783A (es) Anticuerpos humanizados contra psma.
IL201677A0 (en) Multi-immunoaffinity based antigen identification

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application